Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
Abstract
:1. Introduction
2. The Roles of HER Receptors in Breast Cancers
3. HER Receptors and Cell Signaling
4. Mechanisms Underlying the Action of Trastuzumab
5. Mechanisms Underlying Trastuzumab Resistance
6. Mechanisms Underlying the Action of Pertuzumab
7. The Mechanisms Underlying the Synergism of Trastuzumab and Pertuzumab
8. Other Anti-HER2 Strategies beyond Pertuzumab
9. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Yarden, Y.; Sliwkowski, M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2, 127–137. [Google Scholar] [CrossRef] [PubMed]
- Citri, A.; Yarden, Y. Egf-ErbB signalling: Towards the systems level. Nat. Rev. Mol. Cell Biol. 2006, 7, 505–516. [Google Scholar] [CrossRef] [PubMed]
- Peles, E.; Yarden, Y. Neu and its ligands: From an oncogene to neural factors. BioEssays News Rev. Mol. Cell. Dev. Biol. 1993, 15, 815–824. [Google Scholar] [CrossRef] [PubMed]
- Rajkumar, T.; Gullick, W.J. The type I growth factor receptors in human breast cancer. Breast Cancer Res. Treat. 1994, 29, 3–9. [Google Scholar] [CrossRef] [PubMed]
- Hynes, N.E.; MacDonald, G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 2009, 21, 177–184. [Google Scholar] [CrossRef] [PubMed]
- Spector, N.L.; Blackwell, K.L. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 2009, 27, 5838–5847. [Google Scholar] [CrossRef] [PubMed]
- Cai, Z.; Zhang, H.; Liu, J.; Berezov, A.; Murali, R.; Wang, Q.; Greene, M.I. Targeting ErbB receptors. Semin. Cell Dev. Biol. 2010, 21, 961–966. [Google Scholar] [CrossRef] [PubMed]
- Fiszman, G.L.; Jasnis, M.A. Molecular mechanisms of trastuzumab resistance in HER2 overexpressing breast cancer. Int. J. Breast Cancer 2011, 2011, 352182. [Google Scholar] [CrossRef] [PubMed]
- Mahipal, A.; Kothari, N.; Gupta, S. Epidermal growth factor receptor inhibitors: Coming of age. Cancer Control J. Moffitt Cancer Cent. 2014, 21, 74–79. [Google Scholar] [CrossRef] [PubMed]
- Lluch, A.; Eroles, P.; Perez-Fidalgo, J.A. Emerging EGFR antagonists for breast cancer. Expert Opin. Emerg. Drugs 2014, 19, 165–181. [Google Scholar] [CrossRef] [PubMed]
- Rimawi, M.F.; Schiff, R.; Osborne, C.K. Targeting HER2 for the treatment of breast cancer. Ann. Rev. Med. 2015, 66, 111–128. [Google Scholar] [CrossRef] [PubMed]
- Wang, Z. ErbB receptors and cancer. Methods Mol. Biol. 2017, 1652, 3–35. [Google Scholar] [PubMed]
- Slamon, D.J.; Clark, G.M.; Wong, S.G.; Levin, W.J.; Ullrich, A.; McGuire, W.L. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235, 177–182. [Google Scholar] [CrossRef] [PubMed]
- Slamon, D.J.; Godolphin, W.; Jones, L.A.; Holt, J.A.; Wong, S.G.; Keith, D.E.; Levin, W.J.; Stuart, S.G.; Udove, J.; Ullrich, A. Studies of the her-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244, 707–712. [Google Scholar] [CrossRef] [PubMed]
- Gullick, W.J. The c-ErbB3/HER3 receptor in human cancer. Cancer Surv. 1996, 27, 339–349. [Google Scholar] [PubMed]
- Hynes, N.E.; Lane, H.A. ErbB receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5, 341–354. [Google Scholar] [CrossRef] [PubMed]
- Capdevila, J.; Elez, E.; Macarulla, T.; Ramos, F.J.; Ruiz-Echarri, M.; Tabernero, J. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat. Rev. 2009, 35, 354–363. [Google Scholar] [CrossRef] [PubMed]
- Ross, J.S.; Slodkowska, E.A.; Symmans, W.F.; Pusztai, L.; Ravdin, P.M.; Hortobagyi, G.N. The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14, 320–368. [Google Scholar] [CrossRef] [PubMed]
- De Mattos-Arruda, L.; Cortes, J. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer. Adv. Ther. 2013, 30, 645–658. [Google Scholar] [CrossRef] [PubMed]
- Dawood, S.; Broglio, K.; Buzdar, A.U.; Hortobagyi, G.N.; Giordano, S.H. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review. J. Clin. Oncol. 2010, 28, 92–98. [Google Scholar] [CrossRef] [PubMed]
- Nahta, R.; Yu, D.; Hung, M.C.; Hortobagyi, G.N.; Esteva, F.J. Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer. Nat. Clin. Pract. Oncol. 2006, 3, 269–280. [Google Scholar] [CrossRef] [PubMed]
- Arteaga, C.L.; Sliwkowski, M.X.; Osborne, C.K.; Perez, E.A.; Puglisi, F.; Gianni, L. Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat. Rev. Clin. Oncol. 2012, 9, 16–32. [Google Scholar] [CrossRef] [PubMed]
- Baselga, J.; Cortes, J.; Kim, S.B.; Im, S.A.; Hegg, R.; Im, Y.H.; Roman, L.; Pedrini, J.L.; Pienkowski, T.; Knott, A.; et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 2012, 366, 109–119. [Google Scholar] [CrossRef] [PubMed]
- Gu, G.; Dustin, D.; Fuqua, S.A. Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment. Curr. Opin. Pharmacol. 2016, 31, 97–103. [Google Scholar] [CrossRef] [PubMed]
- Gleeson, J.P.; Keegan, N.M.; Morris, P.G. Adding pertuzumab to trastuzumab and taxanes in HER2 positive breast cancer. Expert Opin. Biol. Ther. 2018, 18, 251–262. [Google Scholar] [CrossRef] [PubMed]
- von Minckwitz, G.; Procter, M.; de Azambuja, E.; Zardavas, D.; Benyunes, M.; Viale, G.; Suter, T.; Arahmani, A.; Rouchet, N.; Clark, E.; et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N. Engl. J. Med. 2017, 377, 122–131. [Google Scholar] [CrossRef] [PubMed]
- Loibl, S.; Gianni, L. HER2-positive breast cancer. Lancet 2017, 389, 2415–2429. [Google Scholar] [CrossRef]
- Perou, C.M.; Sorlie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Rees, C.A.; Pollack, J.R.; Ross, D.T.; Johnsen, H.; Akslen, L.A.; et al. Molecular portraits of human breast tumours. Nature 2000, 406, 747–752. [Google Scholar] [CrossRef] [PubMed]
- Yardley, D.A. Drug resistance and the role of combination chemotherapy in improving patient outcomes. Int. J. Breast Cancer 2013, 2013, 137414. [Google Scholar] [CrossRef] [PubMed]
- Roskoski, R., Jr. The ErbB/her family of protein-tyrosine kinases and cancer. Pharmacol. Res. 2014, 79, 34–74. [Google Scholar] [CrossRef] [PubMed]
- Arteaga, C.L.; Engelman, J.A. ErbB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014, 25, 282–303. [Google Scholar] [CrossRef] [PubMed]
- Hsu, J.L.; Hung, M.C. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev. 2016, 35, 575–588. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lehmann, B.D.; Bauer, J.A.; Chen, X.; Sanders, M.E.; Chakravarthy, A.B.; Shyr, Y.; Pietenpol, J.A. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Investig. 2011, 121, 2750–2767. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Masuda, H.; Zhang, D.; Bartholomeusz, C.; Doihara, H.; Hortobagyi, G.N.; Ueno, N.T. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res. Treat. 2012, 136, 331–345. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Reese, D.M.; Slamon, D.J. HER-2/NEU signal transduction in human breast and ovarian cancer. Stem. Cells 1997, 15, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Bose, R.; Kavuri, S.M.; Searleman, A.C.; Shen, W.; Shen, D.; Koboldt, D.C.; Monsey, J.; Goel, N.; Aronson, A.B.; Li, S.; et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2013, 3, 224–237. [Google Scholar] [CrossRef] [PubMed]
- Natali, P.G.; Nicotra, M.R.; Bigotti, A.; Venturo, I.; Slamon, D.J.; Fendly, B.M.; Ullrich, A. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int. J. Cancer 1990, 45, 457–461. [Google Scholar] [CrossRef] [PubMed]
- Lacroix, H.; Iglehart, J.D.; Skinner, M.A.; Kraus, M.H. Overexpression of ErbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene 1989, 4, 145–151. [Google Scholar] [PubMed]
- Tan, M.; Yao, J.; Yu, D. Overexpression of the c-ErbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 1997, 57, 1199–1205. [Google Scholar] [PubMed]
- Hudziak, R.M.; Schlessinger, J.; Ullrich, A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl. Acad. Sci. USA 1987, 84, 7159–7163. [Google Scholar] [CrossRef] [PubMed]
- Di Fiore, P.P.; Pierce, J.H.; Kraus, M.H.; Segatto, O.; King, C.R.; Aaronson, S.A. ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987, 237, 178–182. [Google Scholar] [CrossRef] [PubMed]
- Pietras, R.J.; Arboleda, J.; Reese, D.M.; Wongvipat, N.; Pegram, M.D.; Ramos, L.; Gorman, C.M.; Parker, M.G.; Sliwkowski, M.X.; Slamon, D.J. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995, 10, 2435–2446. [Google Scholar] [PubMed]
- Burgess, A.W. EGFR family: Structure physiology signalling and therapeutic targets. Growth Factors 2008, 26, 263–274. [Google Scholar] [CrossRef] [PubMed]
- Skinner, A.; Hurst, H.C. Transcriptional regulation of the c-ErbB-3 gene in human breast carcinoma cell lines. Oncogene 1993, 8, 3393–3401. [Google Scholar] [PubMed]
- Jaiswal, B.S.; Kljavin, N.M.; Stawiski, E.W.; Chan, E.; Parikh, C.; Durinck, S.; Chaudhuri, S.; Pujara, K.; Guillory, J.; Edgar, K.A.; et al. Oncogenic ErbB3 mutations in human cancers. Cancer Cell 2013, 23, 603–617. [Google Scholar] [CrossRef] [PubMed]
- Carpenter, G. ErbB-4: Mechanism of action and biology. Exp. Cell Res. 2003, 284, 66–77. [Google Scholar] [CrossRef]
- Jones, F.E. HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer. J. Mammary Gland Biol. Neoplasia 2008, 13, 247–258. [Google Scholar] [CrossRef] [PubMed]
- Hollmen, M.; Elenius, K. Potential of ErbB4 antibodies for cancer therapy. Future Oncol. 2010, 6, 37–53. [Google Scholar] [CrossRef] [PubMed]
- Veikkolainen, V.; Vaparanta, K.; Halkilahti, K.; Iljin, K.; Sundvall, M.; Elenius, K. Function of ErbB4 is determined by alternative splicing. Cell Cycle 2011, 10, 2647–2657. [Google Scholar] [CrossRef] [PubMed]
- Lemmon, M.A.; Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141, 1117–1134. [Google Scholar] [CrossRef] [PubMed]
- Kovacs, E.; Zorn, J.A.; Huang, Y.; Barros, T.; Kuriyan, J. A structural perspective on the regulation of the epidermal growth factor receptor. Ann. Rev. Biochem. 2015, 84, 739–764. [Google Scholar] [CrossRef] [PubMed]
- Ward, C.W.; Hoyne, P.A.; Flegg, R.H. Insulin and epidermal growth factor receptors contain the cysteine repeat motif found in the tumor necrosis factor receptor. Proteins 1995, 22, 141–153. [Google Scholar] [CrossRef] [PubMed]
- Carpenter, G.; Lembach, K.J.; Morrison, M.M.; Cohen, S. Characterization of the binding of 125-I-labeled epidermal growth factor to human fibroblasts. J. Biol. Chem. 1975, 250, 4297–4304. [Google Scholar] [PubMed]
- Ullrich, A.; Coussens, L.; Hayflick, J.S.; Dull, T.J.; Gray, A.; Tam, A.W.; Lee, J.; Yarden, Y.; Libermann, T.A.; Schlessinger, J. Human epidermal growth factor receptor cdna sequence and aberrant expression of the amplified gene in a431 epidermoid carcinoma cells. Nature 1984, 309, 418–425. [Google Scholar] [CrossRef] [PubMed]
- Velu, T.J.; Beguinot, L.; Vass, W.C.; Willingham, M.C.; Merlino, G.T.; Pastan, I.; Lowy, D.R. Epidermal-growth-factor-dependent transformation by a human egf receptor proto-oncogene. Science 1987, 238, 1408–1410. [Google Scholar] [CrossRef] [PubMed]
- Kim, Y.T.; Park, S.W.; Kim, J.W. Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma. Gynecol. Oncol. 2002, 87, 84–89. [Google Scholar] [CrossRef] [PubMed]
- Kopp, R.; Rothbauer, E.; Ruge, M.; Arnholdt, H.; Spranger, J.; Muders, M.; Pfeiffer, D.G.; Schildberg, F.W.; Pfeiffer, A. Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: Evidence for new therapeutic options. Recent Results Cancer Res. 2003, 162, 115–132. [Google Scholar] [PubMed]
- Nicholson, R.I.; Gee, J.M.; Harper, M.E. EGFR and cancer prognosis. Eur. J. Cancer 2001, 37 (Suppl. 4), S9–S15. [Google Scholar] [CrossRef]
- Carraway, K.L., 3rd; Cantley, L.C. A neu acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling. Cell 1994, 78, 5–8. [Google Scholar] [CrossRef]
- Pinkas-Kramarski, R.; Soussan, L.; Waterman, H.; Levkowitz, G.; Alroy, I.; Klapper, L.; Lavi, S.; Seger, R.; Ratzkin, B.J.; Sela, M.; et al. Diversification of NEU differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 1996, 15, 2452–2467. [Google Scholar] [CrossRef] [PubMed]
- Coussens, L.; Yang-Feng, T.L.; Liao, Y.C.; Chen, E.; Gray, A.; McGrath, J.; Seeburg, P.H.; Libermann, T.A.; Schlessinger, J.; Francke, U. Tyrosine kinase receptor with extensive homology to egf receptor shares chromosomal location with neu oncogene. Science 1985, 230, 1132–1139. [Google Scholar] [CrossRef] [PubMed]
- Schlessinger, J.; Ullrich, A. Growth factor signaling by receptor tyrosine kinases. Neuron 1992, 9, 383–391. [Google Scholar] [CrossRef]
- Pawson, T. Protein modules and signalling networks. Nature 1995, 373, 573–580. [Google Scholar] [CrossRef] [PubMed]
- Shih, C.; Padhy, L.C.; Murray, M.; Weinberg, R.A. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981, 290, 261–264. [Google Scholar] [CrossRef] [PubMed]
- Bargmann, C.I.; Hung, M.C.; Weinberg, R.A. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986, 45, 649–657. [Google Scholar] [CrossRef]
- Yonemura, Y.; Ninomiya, I.; Ohoyama, S.; Kimura, H.; Yamaguchi, A.; Fushida, S.; Kosaka, T.; Miwa, K.; Miyazaki, I.; Endou, Y.; et al. Expression of c-ErbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-ErbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. Cancer 1991, 67, 2914–2918. [Google Scholar] [CrossRef]
- Press, M.F.; Pike, M.C.; Hung, G.; Zhou, J.Y.; Ma, Y.; George, J.; Dietz-Band, J.; James, W.; Slamon, D.J.; Batsakis, J.G.; et al. Amplification and overexpression of HER-2/NEU in carcinomas of the salivary gland: Correlation with poor prognosis. Cancer Res. 1994, 54, 5675–5682. [Google Scholar] [PubMed]
- Kraus, M.H.; Issing, W.; Miki, T.; Popescu, N.C.; Aaronson, S.A. Isolation and characterization of ErbB3, a third member of the ErbB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors. Proc. Natl. Acad. Sci. USA 1989, 86, 9193–9197. [Google Scholar] [CrossRef] [PubMed]
- Cacace, A.M.; Guadagno, S.N.; Krauss, R.S.; Fabbro, D.; Weinstein, I.B. The epsilon isoform of protein kinase c is an oncogene when overexpressed in rat fibroblasts. Oncogene 1993, 8, 2095–2104. [Google Scholar] [PubMed]
- Rajkumar, T.; Majhi, U.; Malligarjuna, V.; Gullick, W. Prevalence of c-ErbB3 expression in squamous-cell carcinomas of the cervix as determined by the monoclonal-antibody RTJ2. Int. J. Oncol. 1995, 6, 105–109. [Google Scholar] [CrossRef] [PubMed]
- Prigent, S.A.; Gullick, W.J. Identification of c-ErbB-3 binding sites for phophatidylinositol 3’-kinase and SHC using an EGF receptor/c-ErbB-3 chimera. EMBO J. 1994, 13, 2831–2841. [Google Scholar] [CrossRef] [PubMed]
- Shi, F.; Telesco, S.E.; Liu, Y.; Radhakrishnan, R.; Lemmon, M.A. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc. Natl. Acad. Sci. USA 2010, 107, 7692–7697. [Google Scholar] [CrossRef] [PubMed]
- Sardi, S.P.; Murtie, J.; Koirala, S.; Patten, B.A.; Corfas, G. Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain. Cell 2006, 127, 185–197. [Google Scholar] [CrossRef] [PubMed]
- Kinugasa, Y.; Ishiguro, H.; Tokita, Y.; Oohira, A.; Ohmoto, H.; Higashiyama, S. Neuroglycan C, a novel member of the neuregulin family. Biochem. Biophys. Res. Commun. 2004, 321, 1045–1049. [Google Scholar] [CrossRef] [PubMed]
- Kochupurakkal, B.S.; Harari, D.; Di-Segni, A.; Maik-Rachline, G.; Lyass, L.; Gur, G.; Kerber, G.; Citri, A.; Lavi, S.; Eilam, R.; et al. Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. J. Biol. Chem. 2005, 280, 8503–8512. [Google Scholar] [CrossRef] [PubMed]
- Normanno, N.; Bianco, C.; Strizzi, L.; Mancino, M.; Maiello, M.R.; De Luca, A.; Caponigro, F.; Salomon, D.S. The ErbB receptors and their ligands in cancer: An overview. Curr. Drug Targets 2005, 6, 243–257. [Google Scholar] [CrossRef] [PubMed]
- Franklin, M.C.; Carey, K.D.; Vajdos, F.F.; Leahy, D.J.; de Vos, A.M.; Sliwkowski, M.X. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004, 5, 317–328. [Google Scholar] [CrossRef]
- Lemmon, M.A. Ligand-induced ErbB receptor dimerization. Exp. Cell Res. 2009, 315, 638–648. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ferguson, K.M. Structure-based view of epidermal growth factor receptor regulation. Ann. Rev. Biophys. 2008, 37, 353–373. [Google Scholar] [CrossRef] [PubMed]
- Rotin, D.; Honegger, A.M.; Margolis, B.L.; Ullrich, A.; Schlessinger, J. Presence of SH2 domains of phospholipase C gamma 1 enhances substrate phosphorylation by increasing the affinity toward the epidermal growth factor receptor. J. Biol. Chem. 1992, 267, 9678–9683. [Google Scholar] [PubMed]
- Cohen, B.D.; Kiener, P.A.; Green, J.M.; Foy, L.; Fell, H.P.; Zhang, K. The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. J. Biol. Chem. 1996, 271, 30897–30903. [Google Scholar] [CrossRef] [PubMed]
- Zrihan-Licht, S.; Deng, B.; Yarden, Y.; McShan, G.; Keydar, I.; Avraham, H. CSK homologous kinase, a novel signaling molecule, directly associates with the activated ErbB-2 receptor in breast cancer cells and inhibits their proliferation. J. Biol. Chem. 1998, 273, 4065–4072. [Google Scholar] [CrossRef] [PubMed]
- Keilhack, H.; Tenev, T.; Nyakatura, E.; Godovac-Zimmermann, J.; Nielsen, L.; Seedorf, K.; Bohmer, F.D. Phosphotyrosine 1173 mediates binding of the protein-tyrosine phosphatase SHP-1 to the epidermal growth factor receptor and attenuation of receptor signaling. J. Biol. Chem. 1998, 273, 24839–24846. [Google Scholar] [CrossRef] [PubMed]
- Hellyer, N.J.; Kim, M.S.; Koland, J.G. Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor. J. Biol. Chem. 2001, 276, 42153–42161. [Google Scholar] [CrossRef] [PubMed]
- Schulze, W.X.; Deng, L.; Mann, M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol. Syst. Biol. 2005, 1. [Google Scholar] [CrossRef] [PubMed]
- Kaushansky, A.; Gordus, A.; Budnik, B.A.; Lane, W.S.; Rush, J.; MacBeath, G. System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation that are unusually selective in their recruitment properties. Chem. Biol. 2008, 15, 808–817. [Google Scholar] [CrossRef] [PubMed]
- Wilson, K.J.; Gilmore, J.L.; Foley, J.; Lemmon, M.A.; Riese, D.J., 2nd. Functional selectivity of EGF family peptide growth factors: Implications for cancer. Pharmacol. Ther. 2009, 122, 1–8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sato, K. Cellular functions regulated by phosphorylation of EGFR on TYR845. Int. J. Mol. Sci. 2013, 14, 10761–10790. [Google Scholar] [CrossRef] [PubMed]
- Downward, J. Ras signalling and apoptosis. Curr. Opin. Genet. Dev. 1998, 8, 49–54. [Google Scholar] [CrossRef]
- Castellano, E.; Downward, J. Ras interaction with PI3K: More than just another effector pathway. Genes Cancer 2011, 2, 261–274. [Google Scholar] [CrossRef] [PubMed]
- Burgering, B.M.; Coffer, P.J. Protein kinase b (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995, 376, 599–602. [Google Scholar] [CrossRef] [PubMed]
- Downward, J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell Biol. 1998, 10, 262–267. [Google Scholar] [CrossRef]
- Okano, J.; Gaslightwala, I.; Birnbaum, M.J.; Rustgi, A.K.; Nakagawa, H. Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. J. Biol. Chem. 2000, 275, 30934–30942. [Google Scholar] [CrossRef] [PubMed]
- Skeen, J.E.; Bhaskar, P.T.; Chen, C.-C.; Chen, W.S.; Peng, X.-D.; Nogueira, V.; Hahn-Windgassen, A.; Kiyokawa, H.; Hay, N. Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell. 2006, 10, 269–280. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nuti, M.; Bellati, F.; Visconti, V.; Napoletano, C.; Domenici, L.; Caccetta, J.; Zizzari, I.G.; Ruscito, I.; Rahimi, H.; Benedetti-Panici, P.; et al. Immune effects of trastuzumab. J. Cancer 2011, 2, 317–323. [Google Scholar] [CrossRef] [PubMed]
- Clynes, R.A.; Towers, T.L.; Presta, L.G.; Ravetch, J.V. Inhibitory FC receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 2000, 6, 443–446. [Google Scholar] [CrossRef] [PubMed]
- Arnould, L.; Gelly, M.; Penault-Llorca, F.; Benoit, L.; Bonnetain, F.; Migeon, C.; Cabaret, V.; Fermeaux, V.; Bertheau, P.; Garnier, J.; et al. Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism? Br. J. Cancer 2006, 94, 259–267. [Google Scholar] [CrossRef] [PubMed]
- Varchetta, S.; Gibelli, N.; Oliviero, B.; Nardini, E.; Gennari, R.; Gatti, G.; Silva, L.S.; Villani, L.; Tagliabue, E.; Menard, S.; et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing HER2. Cancer Res. 2007, 67, 11991–11999. [Google Scholar] [CrossRef] [PubMed]
- Kute, T.; Stehle, J.R., Jr.; Ornelles, D.; Walker, N.; Delbono, O.; Vaughn, J.P. Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against HER2 positive breast cancer cells. Oncoimmunology 2012, 1, 810–821. [Google Scholar] [CrossRef] [PubMed]
- Petricevic, B.; Laengle, J.; Singer, J.; Sachet, M.; Fazekas, J.; Steger, G.; Bartsch, R.; Jensen-Jarolim, E.; Bergmann, M. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/NEU breast cancer patients. J. Transl. Med. 2013, 11, 307. [Google Scholar] [CrossRef] [PubMed]
- Duong, M.N.; Cleret, A.; Matera, E.L.; Chettab, K.; Mathe, D.; Valsesia-Wittmann, S.; Clemenceau, B.; Dumontet, C. Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity. Breast Cancer Res. 2015, 17, 57. [Google Scholar] [CrossRef] [PubMed]
- Shi, Y.; Fan, X.; Deng, H.; Brezski, R.J.; Rycyzyn, M.; Jordan, R.E.; Strohl, W.R.; Zou, Q.; Zhang, N.; An, Z. Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with fcgamma receptors on macrophages. J. Immunol. 2015, 194, 4379–4386. [Google Scholar] [CrossRef] [PubMed]
- Scaltriti, M.; Verma, C.; Guzman, M.; Jimenez, J.; Parra, J.L.; Pedersen, K.; Smith, D.J.; Landolfi, S.; Ramon y Cajal, S.; Arribas, J.; et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 2009, 28, 803–814. [Google Scholar] [CrossRef] [PubMed]
- Maadi, H.; Nami, B.; Tong, J.; Li, G.; Wang, Z. The effects of trastuzumab on HER2-mediated cell signaling in cho cells expressing human HER2. BMC Cancer 2018, 18, 238. [Google Scholar] [CrossRef] [PubMed]
- Jochems, C.; Hodge, J.W.; Fantini, M.; Fujii, R.; Morillon, Y.M., 2nd; Greiner, J.W.; Padget, M.R.; Tritsch, S.R.; Tsang, K.Y.; Campbell, K.S.; et al. An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele. Oncotarget 2016, 7, 86359–86373. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sanchez-Martinez, D.; Allende-Vega, N.; Orecchioni, S.; Talarico, G.; Cornillon, A.; Vo, D.N.; Rene, C.; Lu, Z.Y.; Krzywinska, E.; Anel, A.; et al. Expansion of allogeneic nk cells with efficient antibody-dependent cell cytotoxicity against multiple tumors. Theranostics 2018, 8, 3856–3869. [Google Scholar] [CrossRef] [PubMed]
- Bang, Y.J.; Giaccone, G.; Im, S.A.; Oh, D.Y.; Bauer, T.M.; Nordstrom, J.L.; Li, H.; Chichili, G.R.; Moore, P.A.; Hong, S.; et al. First-in-human phase 1 study of margetuximab (MGAH22), an FC-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Ann. Oncol. 2017, 28, 855–861. [Google Scholar] [CrossRef] [PubMed]
- Jo, M.; Kwon, H.S.; Lee, K.H.; Lee, J.C.; Jung, S.T. Engineered aglycosylated full-length IGG FC variants exhibiting improved FCgammariiia binding and tumor cell clearance. mAbs 2018, 10, 278–289. [Google Scholar] [CrossRef] [PubMed]
- Nakajima, T.; Okayama, H.; Ashizawa, M.; Noda, M.; Aoto, K.; Saito, M.; Monma, T.; Ohki, S.; Shibata, M.; Takenoshita, S.; et al. Augmentation of antibody-dependent cellular cytotoxicity with defucosylated monoclonal antibodies in patients with GI-tract cancer. Oncol. Lett. 2018, 15, 2604–2610. [Google Scholar] [CrossRef] [PubMed]
- Evans, M.K.; Sauer, S.J.; Nath, S.; Robinson, T.J.; Morse, M.A.; Devi, G.R. X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity. Cell Death Dis. 2016, 7, e2073. [Google Scholar] [CrossRef] [PubMed]
- Xu, F.; Sunderland, A.; Zhou, Y.; Schulick, R.D.; Edil, B.H.; Zhu, Y. Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions. Cancer Immunol. Immunother. CII 2017, 66, 1367–1375. [Google Scholar] [CrossRef] [PubMed]
- Pham, D.H.; Kim, J.S.; Kim, S.K.; Shin, D.J.; Uong, N.T.; Hyun, H.; Yoon, M.S.; Kang, S.J.; Ryu, Y.J.; Cho, J.S.; et al. Effects of adam10 and adam17 inhibitors on natural killer cell expansion and antibody-dependent cellular cytotoxicity against breast cancer cells in vitro. Anticancer Res. 2017, 37, 5507–5513. [Google Scholar] [PubMed]
- Di Modica, M.; Sfondrini, L.; Regondi, V.; Varchetta, S.; Oliviero, B.; Mariani, G.; Bianchi, G.V.; Generali, D.; Balsari, A.; Triulzi, T.; et al. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. Oncotarget 2016, 7, 255–265. [Google Scholar] [CrossRef] [PubMed]
- Okita, R.; Shimizu, K.; Nojima, Y.; Yukawa, T.; Maeda, A.; Saisho, S.; Nakata, M. Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells. Oncol. Rep. 2015, 34, 2864–2870. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Collins, D.M.; Gately, K.; Hughes, C.; Edwards, C.; Davies, A.; Madden, S.F.; O’Byrne, K.J.; O’Donovan, N.; Crown, J. Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines. Cell. Immunol. 2017, 319, 35–42. [Google Scholar] [CrossRef] [PubMed]
- Gijsen, M.; King, P.; Perera, T.; Parker, P.J.; Harris, A.L.; Larijani, B.; Kong, A. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 HERceptin in breast cancer. PLoS Biol. 2010, 8, e1000563. [Google Scholar] [CrossRef] [PubMed]
- Dokmanovic, M.; Wu, Y.; Shen, Y.; Chen, J.; Hirsch, D.S.; Wu, W.J. Trastuzumab-induced recruitment of CSK-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition. Cancer Biol. Ther. 2014, 15, 1029–1041. [Google Scholar] [CrossRef] [PubMed]
- Yakes, F.M.; Chinratanalab, W.; Ritter, C.A.; King, W.; Seelig, S.; Arteaga, C.L. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002, 62, 4132–4141. [Google Scholar] [PubMed]
- Xia, W.; Bisi, J.; Strum, J.; Liu, L.; Carrick, K.; Graham, K.M.; Treece, A.L.; Hardwicke, M.A.; Dush, M.; Liao, Q.; et al. Regulation of survivin by ErbB2 signaling: Therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res. 2006, 66, 1640–1647. [Google Scholar] [CrossRef] [PubMed]
- Cuello, M.; Ettenberg, S.A.; Clark, A.S.; Keane, M.M.; Posner, R.H.; Nau, M.M.; Dennis, P.A.; Lipkowitz, S. Down-regulation of the ErbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress ErbB-2. Cancer Res. 2001, 61, 4892–4900. [Google Scholar] [PubMed]
- Austin, C.D.; De Maziere, A.M.; Pisacane, P.I.; van Dijk, S.M.; Eigenbrot, C.; Sliwkowski, M.X.; Klumperman, J.; Scheller, R.H. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol. Biol. Cell 2004, 15, 5268–5282. [Google Scholar] [CrossRef] [PubMed]
- Valabrega, G.; Montemurro, F.; Sarotto, I.; Petrelli, A.; Rubini, P.; Tacchetti, C.; Aglietta, M.; Comoglio, P.M.; Giordano, S. TGFalpha expression impairs trastuzumab-induced HER2 downregulation. Oncogene 2005, 24, 3002–3010. [Google Scholar] [CrossRef] [PubMed]
- Longva, K.E.; Pedersen, N.M.; Haslekas, C.; Stang, E.; Madshus, I.H. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int. J. Cancer 2005, 116, 359–367. [Google Scholar] [CrossRef] [PubMed]
- Merry, C.R.; McMahon, S.; Thompson, C.L.; Miskimen, K.L.; Harris, L.N.; Khalil, A.M. Integrative transcriptome-wide analyses reveal critical HER2-regulated mRNAs and lincRNAs in HER2+ breast cancer. Breast Cancer Res. Treat. 2015, 150, 321–334. [Google Scholar] [CrossRef] [PubMed]
- Christianson, T.A.; Doherty, J.K.; Lin, Y.J.; Ramsey, E.E.; Holmes, R.; Keenan, E.J.; Clinton, G.M. NH2-terminally truncated HER-2/NEU protein: Relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res. 1998, 58, 5123–5129. [Google Scholar] [PubMed]
- Molina, M.A.; Codony-Servat, J.; Albanell, J.; Rojo, F.; Arribas, J.; Baselga, J. Trastuzumab (herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001, 61, 4744–4749. [Google Scholar] [PubMed]
- Scaltriti, M.; Rojo, F.; Ocana, A.; Anido, J.; Guzman, M.; Cortes, J.; Di Cosimo, S.; Matias-Guiu, X.; Ramon y Cajal, S.; Arribas, J.; et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl. Cancer Inst. 2007, 99, 628–638. [Google Scholar] [CrossRef] [PubMed]
- Sperinde, J.; Jin, X.; Banerjee, J.; Penuel, E.; Saha, A.; Diedrich, G.; Huang, W.; Leitzel, K.; Weidler, J.; Ali, S.M.; et al. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin. Cancer Res. 2010, 16, 4226–4235. [Google Scholar] [CrossRef] [PubMed]
- Arribas, J.; Esselens, C. Adam17 as a therapeutic target in multiple diseases. Curr. Pharm. Des. 2009, 15, 2319–2335. [Google Scholar] [CrossRef] [PubMed]
- Codony-Servat, J.; Albanell, J.; Lopez-Talavera, J.C.; Arribas, J.; Baselga, J. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res. 1999, 59, 1196–1201. [Google Scholar] [PubMed]
- Yuan, C.X.; Lasut, A.L.; Wynn, R.; Neff, N.T.; Hollis, G.F.; Ramaker, M.L.; Rupar, M.J.; Liu, P.; Meade, R. Purification of HER-2 extracellular domain and identification of its cleavage site. Protein Expr. Purif. 2003, 29, 217–222. [Google Scholar] [CrossRef]
- Pedersen, K.; Angelini, P.D.; Laos, S.; Bach-Faig, A.; Cunningham, M.P.; Ferrer-Ramon, C.; Luque-Garcia, A.; Garcia-Castillo, J.; Parra-Palau, J.L.; Scaltriti, M.; et al. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol. Cell. Biol. 2009, 29, 3319–3331. [Google Scholar] [CrossRef] [PubMed]
- Anido, J.; Scaltriti, M.; Bech Serra, J.J.; Santiago Josefat, B.; Todo, F.R.; Baselga, J.; Arribas, J. Biosynthesis of tumorigenic HER2 c-terminal fragments by alternative initiation of translation. EMBO J. 2006, 25, 3234–3244. [Google Scholar] [CrossRef] [PubMed]
- Molina, M.A.; Saez, R.; Ramsey, E.E.; Garcia-Barchino, M.J.; Rojo, F.; Evans, A.J.; Albanell, J.; Keenan, E.J.; Lluch, A.; Garcia-Conde, J.; et al. NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin. Cancer Res. 2002, 8, 347–353. [Google Scholar] [PubMed]
- Saez, A.; Andreu, F.J.; Segui, M.A.; Bare, M.L.; Fernandez, S.; Dinares, C.; Rey, M. Her-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-a study of two hundred cases. Breast 2006, 15, 519–527. [Google Scholar] [CrossRef] [PubMed]
- Pietras, R.J.; Fendly, B.M.; Chazin, V.R.; Pegram, M.D.; Howell, S.B.; Slamon, D.J. Antibody to HER-2/NEU receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994, 9, 1829–1838. [Google Scholar] [PubMed]
- Pietras, R.J.; Pegram, M.D.; Finn, R.S.; Maneval, D.A.; Slamon, D.J. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998, 17, 2235–2249. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pietras, R.J.; Poen, J.C.; Gallardo, D.; Wongvipat, P.N.; Lee, H.J.; Slamon, D.J. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 1999, 59, 1347–1355. [Google Scholar] [PubMed]
- Izumi, Y.; Xu, L.; di Tomaso, E.; Fukumura, D.; Jain, R.K. Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 2002, 416, 279–280. [Google Scholar] [CrossRef] [PubMed]
- Wen, X.F.; Yang, G.; Mao, W.; Thornton, A.; Liu, J.; Bast, R.C., Jr.; Le, X.F. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: Implications for HER2-targeted antibody therapy. Oncogene 2006, 25, 6986–6996. [Google Scholar] [CrossRef] [PubMed]
- Rexer, B.N.; Arteaga, C.L. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: Mechanisms and clinical implications. Crit. Rev. Oncog. 2012, 17, 1–16. [Google Scholar] [CrossRef] [PubMed]
- Menyhart, O.; Santarpia, L.; Gyorffy, B. A comprehensive outline of trastuzumab resistance biomarkers in HER2 overexpressing breast cancer. Curr. Cancer Drug Targets 2015, 15, 665–683. [Google Scholar] [CrossRef] [PubMed]
- Slamon, D.; Pegram, M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin. Oncol. 2001, 28, 13–19. [Google Scholar] [CrossRef]
- Marty, M.; Cognetti, F.; Maraninchi, D.; Snyder, R.; Mauriac, L.; Tubiana-Hulin, M.; Chan, S.; Grimes, D.; Anton, A.; Lluch, A.; et al. Randomized phase ii trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The m77001 study group. J. Clin. Oncol. 2005, 23, 4265–4274. [Google Scholar] [CrossRef] [PubMed]
- Mittendorf, E.A.; Wu, Y.; Scaltriti, M.; Meric-Bernstam, F.; Hunt, K.K.; Dawood, S.; Esteva, F.J.; Buzdar, A.U.; Chen, H.; Eksambi, S.; et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin. Cancer Res. 2009, 15, 7381–7388. [Google Scholar] [CrossRef] [PubMed]
- Niikura, N.; Liu, J.; Hayashi, N.; Mittendorf, E.A.; Gong, Y.; Palla, S.L.; Tokuda, Y.; Gonzalez-Angulo, A.M.; Hortobagyi, G.N.; Ueno, N.T. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J. Clin. Oncol. 2012, 30, 593–599. [Google Scholar] [CrossRef] [PubMed]
- Lipton, A.; Goodman, L.; Leitzel, K.; Cook, J.; Sperinde, J.; Haddad, M.; Kostler, W.J.; Huang, W.; Weidler, J.M.; Ali, S.; et al. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer. Breast Cancer Res. Treat. 2013, 141, 43–53. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tural, D.; Akar, E.; Mutlu, H.; Kilickap, S. P95 HER2 fragments and breast cancer outcome. Expert Rev. Anticancer Ther. 2014, 14, 1089–1096. [Google Scholar] [CrossRef] [PubMed]
- Yonemori, K.; Tsuta, K.; Shimizu, C.; Hatanaka, Y.; Hirakawa, A.; Ono, M.; Kouno, T.; Katsumata, N.; Ando, M.; Tamura, K.; et al. Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. J. Surg. Oncol. 2010, 101, 222–227. [Google Scholar] [CrossRef] [PubMed]
- Gallardo, A.; Lerma, E.; Escuin, D.; Tibau, A.; Munoz, J.; Ojeda, B.; Barnadas, A.; Adrover, E.; Sanchez-Tejada, L.; Giner, D.; et al. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br. J. Cancer 2012, 106, 1367–1373. [Google Scholar] [CrossRef] [PubMed]
- Zhuang, G.; Brantley-Sieders, D.M.; Vaught, D.; Yu, J.; Xie, L.; Wells, S.; Jackson, D.; Muraoka-Cook, R.; Arteaga, C.; Chen, J. Elevation of receptor tyrosine kinase epha2 mediates resistance to trastuzumab therapy. Cancer Res. 2010, 70, 299–308. [Google Scholar] [CrossRef] [PubMed]
- Joshi, J.P.; Brown, N.E.; Griner, S.E.; Nahta, R. Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells. Biochem. Pharmacol. 2011, 82, 1090–1099. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jensen, J.D.; Knoop, A.; Laenkholm, A.V.; Grauslund, M.; Jensen, M.B.; Santoni-Rugiu, E.; Andersson, M.; Ewertz, M. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann. Oncol. 2012, 23, 2034–2042. [Google Scholar] [CrossRef] [PubMed]
- Nagata, Y.; Lan, K.H.; Zhou, X.; Tan, M.; Esteva, F.J.; Sahin, A.A.; Klos, K.S.; Li, P.; Monia, B.P.; Nguyen, N.T.; et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6, 117–127. [Google Scholar] [CrossRef] [PubMed]
- Berns, K.; Horlings, H.M.; Hennessy, B.T.; Madiredjo, M.; Hijmans, E.M.; Beelen, K.; Linn, S.C.; Gonzalez-Angulo, A.M.; Stemke-Hale, K.; Hauptmann, M.; et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12, 395–402. [Google Scholar] [CrossRef] [PubMed]
- Kataoka, Y.; Mukohara, T.; Shimada, H.; Saijo, N.; Hirai, M.; Minami, H. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann. Oncol. 2010, 21, 255–262. [Google Scholar] [CrossRef] [PubMed]
- Razis, E.; Bobos, M.; Kotoula, V.; Eleftheraki, A.G.; Kalofonos, H.P.; Pavlakis, K.; Papakostas, P.; Aravantinos, G.; Rigakos, G.; Efstratiou, I.; et al. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res. Treat. 2011, 128, 447–456. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Esteva, F.J.; Guo, H.; Zhang, S.; Santa-Maria, C.; Stone, S.; Lanchbury, J.S.; Sahin, A.A.; Hortobagyi, G.N.; Yu, D. PTEN, PIK3CA, p-Akt, and p-p70s6k status: Association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am. J. Pathol. 2010, 177, 1647–1656. [Google Scholar] [CrossRef] [PubMed]
- Dave, B.; Migliaccio, I.; Gutierrez, M.C.; Wu, M.F.; Chamness, G.C.; Wong, H.; Narasanna, A.; Chakrabarty, A.; Hilsenbeck, S.G.; Huang, J.; et al. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J. Clin. Oncol. 2011, 29, 166–173. [Google Scholar] [CrossRef] [PubMed]
- Musolino, A.; Naldi, N.; Bortesi, B.; Pezzuolo, D.; Capelletti, M.; Missale, G.; Laccabue, D.; Zerbini, A.; Camisa, R.; Bisagni, G.; et al. Immunoglobulin g fragment c receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/NEU-positive metastatic breast cancer. J. Clin. Oncol. 2008, 26, 1789–1796. [Google Scholar] [CrossRef] [PubMed]
- Tamura, K.; Shimizu, C.; Hojo, T.; Akashi-Tanaka, S.; Kinoshita, T.; Yonemori, K.; Kouno, T.; Katsumata, N.; Ando, M.; Aogi, K.; et al. FcGammar2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann. Oncol. 2011, 22, 1302–1307. [Google Scholar] [CrossRef] [PubMed]
- Gong, C.; Yao, Y.; Wang, Y.; Liu, B.; Wu, W.; Chen, J.; Su, F.; Yao, H.; Song, E. Up-regulation of MIR-21 mediates resistance to trastuzumab therapy for breast cancer. J. Biol. Chem. 2011, 286, 19127–19137. [Google Scholar] [CrossRef] [PubMed]
- Jung, S.T.; Kelton, W.; Kang, T.H.; Ng, D.T.; Andersen, J.T.; Sandlie, I.; Sarkar, C.A.; Georgiou, G. Effective phagocytosis of low HER2 tumor cell lines with engineered, aglycosylated IGG displaying high FCgammariia affinity and selectivity. ACS Chem. Biol. 2013, 8, 368–375. [Google Scholar] [CrossRef] [PubMed]
- Mercogliano, M.F.; De Martino, M.; Venturutti, L.; Rivas, M.A.; Proietti, C.J.; Inurrigarro, G.; Frahm, I.; Allemand, D.H.; Deza, E.G.; Ares, S.; et al. Tnfalpha-induced mucin 4 expression elicits trastuzumab resistance in HER2-positive breast cancer. Clin. Cancer Res. 2017, 23, 636–648. [Google Scholar] [CrossRef] [PubMed]
- Nahta, R.; O’Regan, R.M. Evolving strategies for overcoming resistance to HER2-directed therapy: Targeting the PI3K/Akt/mTOR pathway. Clin. Breast Cancer 2010, 10 (Suppl. 3), S72–S78. [Google Scholar] [CrossRef] [PubMed]
- Wilks, S.T. Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway. Breast 2015, 24, 548–555. [Google Scholar] [CrossRef] [PubMed]
- Garcia-Garcia, C.; Ibrahim, Y.H.; Serra, V.; Calvo, M.T.; Guzman, M.; Grueso, J.; Aura, C.; Perez, J.; Jessen, K.; Liu, Y.; et al. Dual mtorc1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin. Cancer Res. 2012, 18, 2603–2612. [Google Scholar] [CrossRef] [PubMed]
- O’Brien, N.A.; McDonald, K.; Tong, L.; von Euw, E.; Kalous, O.; Conklin, D.; Hurvitz, S.A.; di Tomaso, E.; Schnell, C.; Linnartz, R.; et al. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of Akt. Clin. Cancer Res. 2014, 20, 3507–3520. [Google Scholar] [CrossRef] [PubMed]
- Rexer, B.N.; Chanthaphaychith, S.; Dahlman, K.; Arteaga, C.L. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. Breast Cancer Res. 2014, 16, R9. [Google Scholar] [CrossRef] [PubMed]
- Elster, N.; Cremona, M.; Morgan, C.; Toomey, S.; Carr, A.; O’Grady, A.; Hennessy, B.T.; Eustace, A.J. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor bay 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib. Breast Cancer Res. Treat. 2015, 149, 373–383. [Google Scholar] [CrossRef] [PubMed]
- Agus, D.B.; Akita, R.W.; Fox, W.D.; Lewis, G.D.; Higgins, B.; Pisacane, P.I.; Lofgren, J.A.; Tindell, C.; Evans, D.P.; Maiese, K.; et al. Targeting ligand-activated ERBB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002, 2, 127–137. [Google Scholar] [CrossRef]
- Nahta, R.; Hung, M.C.; Esteva, F.J. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004, 64, 2343–2346. [Google Scholar] [CrossRef] [PubMed]
- Takai, N.; Jain, A.; Kawamata, N.; Popoviciu, L.M.; Said, J.W.; Whittaker, S.; Miyakawa, I.; Agus, D.B.; Koeffler, H.P. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer 2005, 104, 2701–2708. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sak, M.M.; Szymanska, M.; Bertelsen, V.; Hasmann, M.; Madshus, I.H.; Stang, E. Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3. Carcinogenesis 2013, 34, 2031–2038. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Khalil, H.S.; Langdon, S.P.; Goltsov, A.; Soininen, T.; Harrison, D.J.; Bown, J.; Deeni, Y.Y. A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells. Oncotarget 2016, 7, 75874–75901. [Google Scholar] [CrossRef] [PubMed]
- Swain, S.M.; Clark, E.; Baselga, J. Treatment of HER2-positive metastatic breast cancer. N. Engl. J. Med. 2015, 372, 1964–1965. [Google Scholar] [CrossRef] [PubMed]
- Ponde, N.; Brandao, M.; El-Hachem, G.; Werbrouck, E.; Piccart, M. Treatment of advanced HER2-positive breast cancer: 2018 and beyond. Cancer Treat. Rev. 2018, 67, 10–20. [Google Scholar] [CrossRef] [PubMed]
- Scheuer, W.; Friess, T.; Burtscher, H.; Bossenmaier, B.; Endl, J.; Hasmann, M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009, 69, 9330–9336. [Google Scholar] [CrossRef] [PubMed]
- Yamashita-Kashima, Y.; Iijima, S.; Yorozu, K.; Furugaki, K.; Kurasawa, M.; Ohta, M.; Fujimoto-Ouchi, K. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin. Cancer Res. 2011, 17, 5060–5070. [Google Scholar] [CrossRef] [PubMed]
- Faratian, D.; Zweemer, A.J.; Nagumo, Y.; Sims, A.H.; Muir, M.; Dodds, M.; Mullen, P.; Um, I.; Kay, C.; Hasmann, M.; et al. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies. Clin. Cancer Res. 2011, 17, 4451–4461. [Google Scholar] [CrossRef] [PubMed]
- Sims, A.H.; Zweemer, A.J.; Nagumo, Y.; Faratian, D.; Muir, M.; Dodds, M.; Um, I.; Kay, C.; Hasmann, M.; Harrison, D.J.; et al. Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer. Br. J. Cancer 2012, 106, 1779–1789. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Richard, S.; Selle, F.; Lotz, J.P.; Khalil, A.; Gligorov, J.; Soares, D.G. Pertuzumab and trastuzumab: The rationale way to synergy. An. Acad. Bras. Cienc. 2016, 88 (Suppl. 1), 565–577. [Google Scholar] [CrossRef] [PubMed]
- Goltsov, A.; Deeni, Y.; Khalil, H.S.; Soininen, T.; Kyriakidis, S.; Hu, H.; Langdon, S.P.; Harrison, D.J.; Bown, J. Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy. Cells 2014, 3, 563–591. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fuentes, G.; Scaltriti, M.; Baselga, J.; Verma, C.S. Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (HER2) from colocalization: An in silico based mechanism. Breast Cancer Res. 2011, 13, R54. [Google Scholar] [CrossRef] [PubMed]
- Fabi, A.; Mottolese, M.; Segatto, O. Therapeutic targeting of ErbB2 in breast cancer: Understanding resistance in the laboratory and combating it in the clinic. J. Mol. Med. 2014, 92, 681–695. [Google Scholar] [CrossRef] [PubMed]
- Ghosh, R.; Narasanna, A.; Wang, S.E.; Liu, S.; Chakrabarty, A.; Balko, J.M.; Gonzalez-Angulo, A.M.; Mills, G.B.; Penuel, E.; Winslow, J.; et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res. 2011, 71, 1871–1882. [Google Scholar] [CrossRef] [PubMed]
- Junttila, T.T.; Akita, R.W.; Parsons, K.; Fields, C.; Lewis Phillips, G.D.; Friedman, L.S.; Sampath, D.; Sliwkowski, M.X. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15, 429–440. [Google Scholar] [CrossRef] [PubMed]
- Sakai, K.; Yokote, H.; Murakami-Murofushi, K.; Tamura, T.; Saijo, N.; Nishio, K. Pertuzumab, a novel her dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway. Cancer Sci. 2007, 98, 1498–1503. [Google Scholar] [CrossRef] [PubMed]
- Hu, S.; Sun, Y.; Meng, Y.; Wang, X.; Yang, W.; Fu, W.; Guo, H.; Qian, W.; Hou, S.; Li, B.; et al. Molecular architecture of the ErbB2 extracellular domain homodimer. Oncotarget 2015, 6, 1695–1706. [Google Scholar] [CrossRef] [PubMed]
- Mohan, N.; Shen, Y.; Endo, Y.; ElZarrad, M.K.; Wu, W.J. Trastuzumab, but not pertuzumab, dysregulates HER2 signaling to mediate inhibition of autophagy and increase in reactive oxygen species production in human cardiomyocytes. Mol. Cancer Ther. 2016, 15, 1321–1331. [Google Scholar] [CrossRef] [PubMed]
- Diessner, J.; Bruttel, V.; Becker, K.; Pawlik, M.; Stein, R.; Hausler, S.; Dietl, J.; Wischhusen, J.; Honig, A. Targeting breast cancer stem cells with HER2-specific antibodies and natural killer cells. Am. J. Cancer Res. 2013, 3, 211–220. [Google Scholar] [PubMed]
- Lua, W.H.; Gan, S.K.; Lane, D.P.; Verma, C.S. A search for synergy in the binding kinetics of trastuzumab and pertuzumab whole and F(AB) to HER2. NPJ Breast Cancer 2015, 1, 15012. [Google Scholar] [CrossRef] [PubMed]
- Verma, S.; Miles, D.; Gianni, L.; Krop, I.E.; Welslau, M.; Baselga, J.; Pegram, M.; Oh, D.Y.; Dieras, V.; Guardino, E.; et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2012, 367, 1783–1791. [Google Scholar] [CrossRef] [PubMed]
- Baselga, J.; Coleman, R.E.; Cortes, J.; Janni, W. Advances in the management of HER2-positive early breast cancer. Crit. Rev. Oncol. Hematol. 2017, 119, 113–122. [Google Scholar] [CrossRef] [PubMed]
- Cimino-Mathews, A.; Foote, J.B.; Emens, L.A. Immune targeting in breast cancer. Oncology 2015, 29, 375–385. [Google Scholar] [PubMed]
- Geuijen, C.A.W.; De Nardis, C.; Maussang, D.; Rovers, E.; Gallenne, T.; Hendriks, L.J.A.; Visser, T.; Nijhuis, R.; Logtenberg, T.; de Kruif, J.; et al. Unbiased combinatorial screening identifies a bispecific IGG1 that potently inhibits HER3 signaling via HER2-guided ligand blockade. Cancer Cell 2018, 33, 922–936. [Google Scholar] [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nami, B.; Maadi, H.; Wang, Z. Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer. Cancers 2018, 10, 342. https://doi.org/10.3390/cancers10100342
Nami B, Maadi H, Wang Z. Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer. Cancers. 2018; 10(10):342. https://doi.org/10.3390/cancers10100342
Chicago/Turabian StyleNami, Babak, Hamid Maadi, and Zhixiang Wang. 2018. "Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer" Cancers 10, no. 10: 342. https://doi.org/10.3390/cancers10100342